MHP
FENC icon

Manatuck Hill Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Manatuck Hill Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,200
Closed -$251K – 119
2025
Q2 		$251K Buy
+30,200
New +$207K 0.09% 110

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Manatuck Hill Partners's FENC Position: Q3 2025 in Review

Manatuck Hill Partners sold out of Fennec Pharmaceuticals (FENC) in Q3 2025, closing a stake of 30,200 shares — an estimated $251K sold.

Manatuck Hill Partners first reported a position in FENC in Q2 2025 and held it in 1 quarter. The position peaked at $251K in Q2 2025. 84 funds tracked by Wall St. Rank hold FENC as of Q3 2025.

  • Manatuck Hill Partners reported no remaining Fennec Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Manatuck Hill Partners sold 30,200 Fennec Pharmaceuticals shares in Q3 2025, an estimated $251K.
  • Manatuck Hill Partners first reported a position in Fennec Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Manatuck Hill Partners's Fennec Pharmaceuticals position peaked at $251K in Q2 2025.
  • 84 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2025.

Based on Manatuck Hill Partners's 13F filing for Q3 2025, filed 14 Nov 2025.